BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its HIF-1a (hypoxia-inducible factor 1a) antagonist, a highly-visible, well-validated target in many cancer types, including solid tumors.
